GLP-1 drugs and surgery: is the 2-week rule actually backed by evidence?

What did @timothy.mountcastle actually say?

The creator's core message, pieced through a choppy transcript, is this: hospitals require patients to stop GLP-1 medications like Ozempic and Mounjaro two weeks before surgery to prevent aspiration during intubation. "Must stop this prior to being intubated," he says, framing it as a patient safety issue tied to gastric emptying delays. The claim is directionally correct, but the delivery is thin on specifics and slightly off on mechanism framing.

To be fair, the two-week figure and the aspiration risk connection are both clinically grounded. What's missing is any nuance about patient type, drug half-life differences between agents, or what patients on these meds for diabetes specifically should do before making any changes. That's not a minor omission when your audience includes people managing blood sugar.

Does the science back this up?

Mostly, yes. GLP-1 receptor agonists are well-documented to slow gastric emptying, a property that's actually part of their weight-loss mechanism. The concern in surgical settings is real: if food stays in the stomach longer than expected, anesthesia induction raises the risk of pulmonary aspiration, which can be life-threatening.

A 2023 case series published in Anaesthesia (Dixit et al., 2023) described patients on semaglutide who had retained gastric contents despite following standard nil-by-mouth guidelines. That paper helped push major anesthesiology societies to issue formal guidance. The American Society of Anesthesiologists released a 2023 advisory recommending that patients on weekly GLP-1 dosing consider holding the medication for one week before elective procedures, with stronger consideration for two weeks in higher-risk cases. Some surgical centers moved to the two-week standard across the board, which appears to be what this creator's facility does. That's a defensible, conservative approach.

What did they get wrong (or right)?

The two-week recommendation is defensible but not universally standardized. The ASA's 2023 guidance actually says one week for weekly-dosed agents as a starting point, with two weeks for patients who have GI symptoms or other risk factors. Blanket two-week stops for all GLP-1 users is on the cautious end of evidence-based practice, not the consensus standard. Calling it a universal hospital requirement overstates the uniformity across institutions.

The creator also bundles all GLP-1s together without noting meaningful pharmacokinetic differences. Semaglutide has a half-life of roughly seven days. Liraglutide is closer to 13 hours. Tirzepatide, a dual GIP/GLP-1 agonist, has a half-life of about five days. A one-size-fits-all window ignores those differences. To be clear, he gets the core safety logic right. Aspiration risk from delayed gastric emptying is real and documented. The error is in the oversimplification, not the underlying concern.

What should you actually know?

If you are on a GLP-1 medication and have surgery scheduled, do not stop it based on a TikTok video. Talk to your prescribing provider and your anesthesiologist together. This is not a bureaucratic suggestion. Stopping a GLP-1 abruptly when you are using it to manage type 2 diabetes can affect blood sugar control in the perioperative period, which carries its own documented risks.

The ASA's 2023 advisory is publicly available and worth reading. It recommends a risk-based conversation, not a blanket rule. Your surgeon may have a facility-specific protocol that differs. Some patients may need imaging or a point-of-care gastric ultrasound before induction to confirm stomach contents regardless of hold duration. The safest thing you can do is disclose every medication you take, including GLP-1s, to your surgical team well in advance of your procedure date.

• Do not adjust your GLP-1 dose or timing without speaking to your prescriber first.
• Inform your anesthesiologist that you are on a GLP-1 medication as early as possible in the surgical planning process.
• Ask specifically whether your facility follows a one-week or two-week hold protocol and why.